Transvaginal Mesh and Vaginal Sling Products Pose a Risk of Serious Injury from Life-Threatening Side Effects
For women experiencing Pelvic Organ Prolapse (POP) or Stress Urinary Incontinence (SUI), placement of transvaginal surgical mesh was intended to help reinforce the weakened vaginal or urethral walls. Ideally, the permanently implanted surgical mesh would repair POP and/or treat urinary incontinence. In 2008 the United States Food and Drug Administration (FDA) noticed that the number […]
Merck Failed to Adequately Warn That Propecia is Associated With Permanent Impotence, Erectile Dysfunction, Depression, Endocrine Crash and Other Harmful Side Effects
The Levensten Law Firm is currently investigating the filing of Propecia lawsuits against Merck for its failure to adequately warn of Propecia’s harmful side effects. Studies show that Propecia is associated with permanent impotence, erectile dysfunction, depression, endocrine crash and other harmful side effects. By way of background, Propecia is marketed to treat male-pattern baldness […]
Bayer Attacks Philadelphia County Mass Tort Program Seeking to Scatter Yaz Victims’ Cases Across The Country to Gain Advantage in Yaz Litigation
In an effort to gain an advantage in the Yaz, Yasmin and Ocella personal injury litigation, Bayer launched an assault on the Philadelphia County Mass Tort program and the experienced judges who administer it. Bayer recently filed a King’s Bench petition asking the Pennsylvania Supreme Court to hold that the Philadelphia County Mass Tort program […]
An Explanation of How Actos Lawsuits Are Handled In State Courts and Federal Courts
Earlier this year, the public was alerted that the diabetes medication, Actos, causes bladder cancer. It did not take long for the FDA and the public to discover that the manufacturer of Actos tragically failed to adequately warn and properly study the risk of bladder cancer. Takeda, the manufacturer of Actos, deprived physicians of the […]
Background Information about Actos and Bladder Cancer
ACTOS ASSOCIATION WITH BLADDER CANCER In 1999 with Actos received FDA approval to treat type II diabetes. Before getting approval for Actos, Takeda knew that it would cause casastrophic side effects, including bladder cancer. Animal studies showed a signal for bladder cancer risk. Takeda knew that they should have studied the bladder cancer risk further. […]
Important Details About FDA’s Dec. 8, 2011 Meeting About Birth Control Such As Yaz and Yasmin
The FDA’s joint meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee will be held on December 8, 2011, from 8 a.m. to 5 p.m. The location is The Marriott Inn and Conference Center, University of Maryland University College, The Ballroom, 3501 University Blvd. East, Adelphi, […]
FDA Posts Questions and Answers About Increased Risks of Blood Clots With Birth Control Like Yaz and Yasmin
The FDA has posted questions and answers that provide a safety overview of Yaz and Yasmin. The link to the questions and answers is: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm273039.htm The FDA provides answers to the following questions: Q1. What is drospirenone? Q2. Which birth control pills (oral contraceptives) contain drospirenone? Q3. What is a venous thromboembolic event (VTE)? Q4. […]
FDA To Hold Meeting on December 8, 2011 About Safety of Yaz and Yasmin
On December 8, 2011, the FDA is holding a meeting of the Reproductive Health Drugs Advisory Committee and the Drug and Safety Risk Management Committee to discuss the risk of blood clots in drugs such as Yaz and Yasmin that contain drospirenone. This is on the heels of the release of the FDA’s study showing […]
FDA Landmark Study on the risks of Birth control such as Yaz, Yasmin, Ocella, Nuvaring and Ortho Evra
Breaking news was released from the FDA this morning concerning a landmark study of the risk of arterial and venous cardiovascular complications caused by Yaz, Yasmin and Ocella. Until now, there was limited data available regarding the risk of venus thromboembolism (VTE) (deep venous thrombosis [DVT] and pulmonary embolism [PE]) in combined hormonal contraceptives (CHCs), […]
